G. A. Wiseman

Articles by G. A. Wiseman

Ibritumomab Tiuxetan Radioimmunotherapy Is Safe and Well Tolerated in Patients With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

ByT. E. Witzig,Leo I. Gordon, MD,G. A. Wiseman,S. Spies,C. Emmanouilides,Myron S. Czuczman, MD,I. W. Flinn,N. L. Barlett,J. L. Murray,B. Alkuzweny,Pratik S. Multani, MD,A. J. Grillo-Lopez, MD,Christine A. White, MD

March 1st 2001

Ibritumomab tiuxetan (Zevalin) consists of an anti-CD20 murine IgG1 kappa monoclonal antibody covalently bound to tiuxetan (MX-DTPA), which stably chelates yttrium-90 for therapy. Ibritumomab tiuxetan therapy involves pretreatment with

Final Results of a Randomized Controlled Study of the Ibritumomab Tiuxetan Radioimmunotherapy Regimen vs a Standard Course of Rituximab Immunotherapy for B-Cell Non-Hodgkin’s Lymphoma

ByT. E. Witzig,Christine A. White, MD,Leo I. Gordon, MD,J. L. Murray,G. A. Wiseman,C. Emmanouilides,Myron S. Czuczman, MD,D. Shen,Pratik S. Multani, MD,A. J. Grillo-Lopez, MD

March 1st 2001

Ibritumomab tiuxetan (Zevalin) is a murine anti-CD20 monoclonal antibody covalently bound to the chelator tiuxetan, which can securely chelate yttrium-90. We performed a randomized controlled trial

G. A. Wiseman

Articles by G. A. Wiseman

Ibritumomab Tiuxetan Radioimmunotherapy Is Safe and Well Tolerated in Patients With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

Final Results of a Randomized Controlled Study of the Ibritumomab Tiuxetan Radioimmunotherapy Regimen vs a Standard Course of Rituximab Immunotherapy for B-Cell Non-Hodgkin’s Lymphoma

Latest Updated Articles

Trending on CancerNetwork

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

FDA Approves Revumenib in R/R NPM1-Mutant AML

Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma